Press Release

 

River Stone Biotech Inc. Announces Issuance of U.S. Patent to Protect Their More Efficient Buprenorphine Production  Process.

 

Jul. 19, 2022

River Stone Biotech Inc., (RSB) a business operating within the contract development and manufacturing space (CDMO) centred around a disruptive specialty API offering, today announced the issuance of a U.S. Patent covering a unique production technology for the preparation of Buprenorphine. The process is higher efficiency and uses more environmentally-friendly reagents than conventional production methods. This production approach is synergistic with RSB’s proprietary methods to produce alkaloid starting materials via fermentation in a cost-effective manner, as described in previously granted US Patent 11,060,071.

U.S. Patent No. 11,390,628 is entitled “Preparation of buprenorphine“ and is expected to provide RSB with protection until 2038.

Paula Hicks, SVP of Technology and IP for RSB, said, “This newly issued U.S. patent expands our rapidly growing and ambitious patent portfolio and further supports the commercial potential of our life saving API’s. The growth of our IP portfolio surrounding both our biological and chemical alkaloid production platform is a core strategic focus for RSB that we believe is creating significant value for both our shareholders and wider stakeholders alike”

Simon Ball, Chief Operating Officer, River Stone, added “This issuance provides further endorsement to the companies long term plans and is testament to the many scientists that have worked, and continue to work, on our novel approach that will soon provide customers the ability to purchase lifesaving API’s that are produced via our exciting, hybrid platform”

 

About River Stone Biotech Inc.

RSB is headquartered in Cambridge, MA, US with development sites in Denmark and Australia; its highly experienced management team has taken multiple projects from concept through method development and into commercial-scale production.  RSB is dedicated to providing life changing APIs and formulations via innovative production methods that blend synthetic biology and chemistry processes.

In the first instance RSB is pleased to be able to make a meaningful contribution to the important Opioid Dependence/Substance Abuse Prevention programs around the world.

River Stone works with a small number of global providers to establish a virtual  cross-functional operation to enable its API offering.

 

For further information please contact:

Simon Ball
River Stone Biotech Inc.

simonb@rstbio.com